Lonza’s New Spheroid-Forming Human Hepatocytes Facilitate Improved In Vitro Liver Model Systems
Walkersville, MD (USA) / Basel (CH), 4 March 2019 – Lonza has further expanded its hepatocytes portfolio characterization with the addition of Verified for Spheroids™ Human Hepatocytes, which are pre-screened for their ability to promote rapid spheroid formation in cell culture. Researchers working in toxicology, disease modeling and DMPK studies can now feel more confident in the performance of Lonza’s hepatocytes in their spheroid and other 3-dimensional (3D) culture platforms.
· 11-13 March, 9:15 am-4:30 pm
· At Booth #3322 at the Baltimore Convention Center
· 11 March, 1:30-3:00 pm
· On Poster P252 at the Baltimore Convention Center
· 13 March, 10:30-11:30am
· In CC Room 338 at the Baltimore Convention Center
Further information can be found at Lonza’s Booth #3322 at ToxExpo 2019, 11-13 March, or by accessing a new technical note and a white paper or via www.lonza.com/sot-2019.
Lonza is an integrated solutions provider that creates value along the Healthcare Continuum®. Through our Pharma & Biotech segment and our Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers' preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases.
Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment and to the preservation and protection of the world where we live.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide. The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion. Further information can be found at www.lonza.com.
Lonza Contact Information
Manager Marketing Communications
Lonza Cologne GmbH
Tel +49 221 991990
Head External Communications
Lonza Group Ltd
Tel +41 61 316 8840
Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.
Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.